Shots:

• The approval is based on DIAMOND-AF trial assessing the safety and efficacy of the DTA system vs contact force-sensing ablation system in 482 patients with recurrent- symptomatic- PAF whose condition is unresponsive to drug therapy
• Results: patient complication rate (96.7% vs 93.4%); primary effectiveness (79.1% vs 75.7%); procedural efficiencies with shorter total RF times- individual RF ablation duration and reduction in volume of infused saline
• The DTA system is the 1st FDA-approved- temperature-controlled- irrigated RF ablation system with diamonds currently available to deliver ablations

 ­ Ref: PRNewswire | Image: Mission Statement Academy